<DOC>
	<DOCNO>NCT00486408</DOCNO>
	<brief_summary>The purpose study intensively characterize immune response , particularly T-cell response , three-dose regimen adenovirus-based HIV-1 vaccine HIV-uninfected adult .</brief_summary>
	<brief_title>Expanded Characterization Immune Response Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given HIV Uninfected Adults</brief_title>
	<detailed_description>This study look relationship among immune response induce MRKAd5 HIV-1 gag/pol/nef vaccine . The study also determine T cell respond different vaccine epitopes correspondingly different functional profile . The study evaluate safety tolerability vaccine regimen well . This study last 60 week . All enrol participant receive vaccination Weeks 0 , 4 , 26 . There 8 20 study visit include screen visit , depend site location . A physical exam , interview , blood collection occur visit . All participant undergo leukapheresis approximately 4 week last vaccination Week 52 . Medical history , HIV test , pregnancy test , HIV risk reduction counsel occur select visit . Additional blood collection occur study collect information relationship immune response efficacy vaccine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Note : As 09/19/07 , enrollment vaccination discontinue . Good general health HIV uninfected Weight 110 pound great Have access participate HIV Vaccine Trials Unit ( HVTU ) willing follow study Willing receive HIV test result Understand vaccination procedure Willing use acceptable method contraception least 21 day prior study entry last study visit HIV vaccine placebos prior HIV trial . Participants provide documentation receive placebo prior HIV trial may eligible . Immunosuppressive medication within 168 day prior first study vaccination Blood product within 90 day prior first study vaccination within 14 day injection Immunoglobulin within 90 day prior first study vaccination within 14 day injection Live attenuate vaccine within 42 day prior first study vaccination within 14 day injection Investigational research agent within 30 day prior first study vaccination Medically indicate subunit kill vaccine within 5 day prior first study vaccination within 14 day injection Allergy treatment antigen injection within 30 day prior first study vaccination Clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health Any medical , psychiatric , social condition , opinion investigator , would interfere study . History anaphylaxis and/or allergy vaccine component Autoimmune disease immunodeficiency Uncontrolled hypertension Bleeding disorder Cancer . Participants surgically remove cancer unlikely recur exclude . Seizure disorder Absence spleen Abnormal laboratory value Mental illness would interfere study Hysterectomy Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>Adenovirus</keyword>
</DOC>